163 related articles for article (PubMed ID: 8154971)
1. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin.
Conti DJ; Freed BM; Gruber SA; Lempert N
Arch Surg; 1994 Apr; 129(4):443-7. PubMed ID: 8154971
[TBL] [Abstract][Full Text] [Related]
2. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
Conti DJ; Freed BM; Singh TP; Gallichio M; Gruber SA; Lempert N
Arch Surg; 1995 Nov; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
[TBL] [Abstract][Full Text] [Related]
3. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
4. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
[TBL] [Abstract][Full Text] [Related]
5. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
6. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
7. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
12. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors.
Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD
Transpl Int; 1992; 5 Suppl 1():S30-1. PubMed ID: 14621725
[TBL] [Abstract][Full Text] [Related]
14. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
[TBL] [Abstract][Full Text] [Related]
15. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
17. Costs and consequences of cytomegalovirus disease.
Schnitzler MA
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
[TBL] [Abstract][Full Text] [Related]
18. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
[TBL] [Abstract][Full Text] [Related]
20. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
Seu P; Winston DJ; Holt CD; Kaldas F; Busuttil RW
Transplantation; 1997 Dec; 64(11):1614-7. PubMed ID: 9415569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]